The search result changed since you submitted your search request. Documents might be displayed in a different sort order.
  • search hit 10 of 15
Back to Result List

Developing a nationwide infrastructure for therapeutic drug monitoring of targeted oral anticancer drugs: the ON-TARGET study protocol

Please always quote using this URN: urn:nbn:de:bvb:20-opus-252196
  • Exposure-efficacy and/or exposure-toxicity relationships have been identified for up to 80% of oral anticancer drugs (OADs). Usually, OADs are administered at fixed doses despite their high interindividual pharmacokinetic variability resulting in large differences in drug exposure. Consequently, a substantial proportion of patients receive a suboptimal dose. Therapeutic Drug Monitoring (TDM), i.e., dosing based on measured drug concentrations, may be used to improve treatment outcomes. The prospective, multicenter, non-interventional ON-TARGETExposure-efficacy and/or exposure-toxicity relationships have been identified for up to 80% of oral anticancer drugs (OADs). Usually, OADs are administered at fixed doses despite their high interindividual pharmacokinetic variability resulting in large differences in drug exposure. Consequently, a substantial proportion of patients receive a suboptimal dose. Therapeutic Drug Monitoring (TDM), i.e., dosing based on measured drug concentrations, may be used to improve treatment outcomes. The prospective, multicenter, non-interventional ON-TARGET study (DRKS00025325) aims to investigate the potential of routine TDM to reduce adverse drug reactions in renal cell carcinoma patients receiving axitinib or cabozantinib. Furthermore, the feasibility of using volumetric absorptive microsampling (VAMS), a minimally invasive and easy to handle blood sampling technique, for sample collection is examined. During routine visits, blood samples are collected and sent to bioanalytical laboratories. Venous and VAMS blood samples are collected in the first study phase to facilitate home-based capillary blood sampling in the second study phase. Within one week, the drug plasma concentrations are measured, interpreted, and reported back to the physician. Patients report their drug intake and toxicity using PRO-CTCAE-based questionnaires in dedicated diaries. Ultimately, the ON-TARGET study aims to develop a nationwide infrastructure for TDM for oral anticancer drugs.show moreshow less

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Metadaten
Author: Anna M. Mc Laughlin, Eduard Schmulenson, Olga Teplytska, Sebastian Zimmermann, Patrick Opitz, Stefanie L. Groenland, Alwin D. R. Huitema, Neeltje Steeghs, Lothar Müller, Stefan Fuxius, Gerald Illerhaus, Markus Joerger, Frank Mayer, Uwe Fuhr, Stefan Holdenrieder, Georg Hempel, Oliver Scherf-Clavel, Ulrich Jaehde, Charlotte Kloft
URN:urn:nbn:de:bvb:20-opus-252196
Document Type:Journal article
Faculties:Fakultät für Chemie und Pharmazie / Institut für Pharmazie und Lebensmittelchemie
Language:English
Parent Title (English):Cancers
ISSN:2072-6694
Year of Completion:2021
Volume:13
Issue:24
Article Number:6281
Source:Cancers (2021) 13:24, 6281. https://doi.org/10.3390/cancers13246281
DOI:https://doi.org/10.3390/cancers13246281
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Tag:oral anticancer drugs; renal cell carcinoma; therapeutic drug monitoring; volumetric absorptive microsampling
Release Date:2022/11/10
Date of first Publication:2021/12/14
Licence (German):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International